Related references
Note: Only part of the references are listed.Off-the-shelf, gene-edited CAR-T cells forge ahead, despite safety scare
Cormac Sheridan
NATURE BIOTECHNOLOGY (2022)
ALPHA Study: ALLO-501 Produced Deep and Durable Responses in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma Comparable to Autologous CAR T
Sattva S. Neelapu et al.
BLOOD (2021)
Development of CAR T-cell lymphoma in 2 of 10 patients effectively treated with piggyBac-modified CD19 CAR T cells
David C. Bishop et al.
BLOOD (2021)
CARAMBA: a first-in-human clinical trial with SLAMF7 CAR-T cells prepared by virus-free Sleeping Beauty gene transfer to treat multiple myeloma
Sabrina Prommersberger et al.
GENE THERAPY (2021)
Gene therapy for severe combined immunodeficiencies and beyond
Alain Fischer et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2020)
The Emerging Landscape of Immune Cell Therapies
Evan W. Weber et al.
CELL (2020)
Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma
Carlos A. Ramos et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy
Kathryn M. Cappell et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
Daniel W. Lee et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
Evaluation of Second Solid Cancers After Hematopoietic Stem Cell Transplantation in European Patients
Andre Tichelli et al.
JAMA ONCOLOGY (2019)
Clonal expansion of CAR T cells harboring lentivector integration in the CBL gene following anti-CD22 CAR T-cell therapy
Nirali N. Shah et al.
BLOOD ADVANCES (2019)
Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma
Catherine M. Bollard et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Chimeric Antigen Receptor Therapy
Carl H. June et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
In Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin's Lymphomas
Carlos A. Ramos et al.
MOLECULAR THERAPY (2018)
Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells
Joseph A. Fraietta et al.
NATURE (2018)
Screening Clinical Cell Products for Replication Competent Retrovirus: The National Gene Vector Biorepository Experience
Kenneth Cornetta et al.
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2018)
Efficacy and Safety of P-Bcma-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Multiple Myeloma (MM)
Tara Gregory et al.
BLOOD (2018)
Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes
Carlos A. Ramos et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma
Andras Heczey et al.
MOLECULAR THERAPY (2017)
Therapeutic T cell engineering
Michel Sadelain et al.
NATURE (2017)
HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells for Progressive Glioblastoma A Phase 1 Dose-Escalation Trial
Nabil Ahmed et al.
JAMA ONCOLOGY (2017)
Toxicities of chimeric antigen receptor T cells: recognition and management
Jennifer N. Brudno et al.
BLOOD (2016)
Acute lymphoblastic leukemia and lymphoma in the context of constitutional mismatch repair deficiency syndrome
Tim Ripperger et al.
EUROPEAN JOURNAL OF MEDICAL GENETICS (2016)
Clinical responses with T lymphocytes targeting malignancy-associated κ light chains
Carlos A. Ramos et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Retroviral vectors and transposons for stable gene therapy: advances, current challenges and perspectives
Jose Eduardo Vargas et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2016)
Prospects for gene-engineered T cell immunotherapy for solid cancers
Christopher A. Klebanoff et al.
NATURE MEDICINE (2016)
Toxicity and management in CAR T-cell therapy
Challice L. Bonifant et al.
MOLECULAR THERAPY-ONCOLYTICS (2016)
Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantation
Xiaoou Zhou et al.
BLOOD (2015)
Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma
Nabil Ahmed et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Evaluating the potential for undesired genomic effects of the piggyBac transposon system in human cells
Sunandan Saha et al.
NUCLEIC ACIDS RESEARCH (2015)
Long-term outcome after haploidentical stem cell transplant and infusion of T cells expressing the inducible caspase 9 safety transgene
Xiaoou Zhou et al.
BLOOD (2014)
Development of Gene Transfer Technology
Richard C. Mulligan
HUMAN GENE THERAPY (2014)
Guidelines for surveillance of individuals with constitutional mismatch repair-deficiency proposed by the European Consortium Care for CMMR-D (C4CMMR-D)
H. F. A. Vasen et al.
JOURNAL OF MEDICAL GENETICS (2014)
Second Cancers in Patients with Neuroendocrine Tumors
Hui-Jen Tsai et al.
PLOS ONE (2013)
Replication-Competent Retroviruses in Gene-Modified T Cells Used in Clinical Trials: Is It Time to Revise the Testing Requirements?
Adham S. Bear et al.
MOLECULAR THERAPY (2012)
Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma
Chrystal U. Louis et al.
BLOOD (2011)
CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients
Barbara Savoldo et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients
Helen E. Heslop et al.
BLOOD (2010)
A new PG13-based packaging cell line for stable production of clinical-grade self-inactivating γ-retroviral vectors using targeted integration
R. Loew et al.
GENE THERAPY (2010)
Cytotoxic T lymphocyte therapy for Epstein-Barr virus Hodgkin's disease
CM Bollard et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2004)
LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1
S Hacein-Bey-Abina et al.
SCIENCE (2003)
Occurrence of leukaemia following gene therapy of X-linked SCID
DB Kohn et al.
NATURE REVIEWS CANCER (2003)
Share Paper
